The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The present disclosure relates to compositions including a phenylbutyrate compound and a bile acid, and methods of processing such compositions.

The present disclosure relates to compositions including a phenylbutyrate compound and a bile acid, and methods of processing such compositions.

The present disclosure relates to compositions including a phenylbutyrate compound and a bile acid, and methods of processing such compositions.

Provided is a pharmaceutical composition for treating and/or preventing fatty liver disease, particularly nonalcoholic fatty liver disease, the pharmaceutical composition having an excellent ACC2-selective inhibitory action and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration.

A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I):

##STR00001## wherein R.sup.1 is haloalkyl or non-aromatic carbocyclyl, R.sup.2 is a hydrogen atom or halogen, R.sup.3 is halogen, ring A is a group represented by the formula:

##STR00002## -L.sup.1- is —O—(CH.sub.2)—, —(CH.sub.2).sub.2—, or the like, R.sup.4 is alkyl or haloalkyl, and R.sup.5 is alkylcarbonyl or carbamoyl, or a pharmaceutically acceptable salt thereof.

Provided is a pharmaceutical composition for treating and/or preventing fatty liver disease, particularly nonalcoholic fatty liver disease, the pharmaceutical composition having an excellent ACC2-selective inhibitory action and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration.

A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I):

##STR00001## wherein R.sup.1 is haloalkyl or non-aromatic carbocyclyl, R.sup.2 is a hydrogen atom or halogen, R.sup.3 is halogen, ring A is a group represented by the formula:

##STR00002## -L.sup.1- is —O—(CH.sub.2)—, —(CH.sub.2).sub.2—, or the like, R.sup.4 is alkyl or haloalkyl, and R.sup.5 is alkylcarbonyl or carbamoyl, or a pharmaceutically acceptable salt thereof.

This invention refers to pharmaceutical compositions containing synergistic combinations of pentacyclic triterpenoids as active principles and denotes that some specific combinations between these types of drugs exhibit effects for the prevention or inhibition of viral infections. The compositions are found in specific quantities and proportions that enhance the pharmacological properties of the compounds, improving their bioavailability and pharmacokinetic properties, while reducing their toxicological and irritability effects, especially in the respiratory tract and the lungs.

A method of treating Parkinson's disease in a subject in need thereof. The method comprises administering a liposomal composition, comprising sphingomyelin in a lipid bilayer and a therapeutically effective amount of GM1, to the subject.

A method of treating Parkinson's disease in a subject in need thereof. The method comprises administering a liposomal composition, comprising sphingomyelin in a lipid bilayer and a therapeutically effective amount of GM1, to the subject.